10.1002/dmrr.3173 Summary Keywords metformin, polycystic ovary syndrome, infertility, mechanism, drug therapy Citation Zeng W, Luo Y, Ou J, Gan D, Huang M, Tomlinson B and Jiang Y (2025) Metformin in polycystic ovary syndrome: unraveling multi-stage therapeutic mechanisms from puberty to long-term health outcomes
Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
While non-steroidal MRAs have not yet been investigated in type 1 diabetes, based on their observed benefits in type 2 diabetes and their mechanism of action, similar kidney-protective effects are anticipated, emphasising the need for dedicated studies with finerenone in people with type 1 diabetes and CKD, including their use in combination with other repurposed therapies such as SGLT2i and GLP1-RAs
The answer: largely through compounding pharmacies and gray-market suppliers
Start with the basics that matter most
Cuando utilizan GLP-1, los pacientes tambin deben consultar a su proveedor para que controle la dosis del medicamento